FindTrial
Sign In

Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-525445-73-00
Enrollment
40
Registered
2026-09-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TMB-high advanced neoplasms

Brief summary

Overall response rate (ORR)

Interventions

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

Sponsors

UZ Brussel
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Overall response rate (ORR)—

Outcome results

None listed

Source: EU CTIS · Data processed: Sep 10, 2026